Navigation Links
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Date:5/7/2009

Conference Call Scheduled for Today - Thursday, May 7, 2009 at 5:30 p.m. Eastern Time

MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for the quarter ended March 31, 2009, and provided an update on its product candidates. The net loss for the quarter, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $6.9 million compared to a net loss of $18.4 million in the comparable period in 2008. Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) at March 31, 2009 of $40.7 million.

"During the first four months of 2009, we have continued to keep pace with our AZ-004 (Staccato(R) loxapine) NDA timeline," said Thomas B. King, President and CEO of Alexza. "Our clinical and regulatory plan is on track, as is the continued scale-up of our commercial manufacturing and quality systems processes. We continue to target our AZ-004 NDA submission for the first quarter of 2010."

Financial Results - Periods Ended March 31, 2009 and 2008

GAAP operating expenses were $16.4 million and $19.2 million in the quarters ended March 31, 2009 and 2008, respectively. In January 2009, the Company announced that it had consolidated its operations, with a primary focus on the continued development of AZ-004 (Staccato loxapine). The restructuring included a workforce reduction of 50 employees, representing approximately 33% of the Company's total workforce. With the reduction in headcount and focus on the development of AZ-004, the Company expects to reduce its expenses by approximately $21.5 million, net of severance costs, for fiscal year 2009, compared to fiscal year 2008, and another reduction of appr
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
2. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
3. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
4. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
8. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
9. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
10. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
11. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   Cypher ... today announced new data showing that, compared to ... technology provided highly equivalent interpretations of whether ... and did so in a fraction of the ... way for more comprehensive genetic analysis in non-invasive ...
(Date:3/27/2015)... 27, 2015 XRpro Sciences, Inc., a ... and development services which features high throughput transporter ... announced financial results for the year ended December ... Chairman of XRpro Sciences commented, "We have completed ... development stage to commercial stage in large part ...
(Date:3/27/2015)... 2015 According to a new ... (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab ... VT, WPW) - Global Forecasts to 2019 ", published by ... around ~$4.73 Billion by 2019 with a CAGR of ... Browse   90   ma ...
Breaking Medicine Technology:New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Instrument announced the award of two contracts from the ... Evaluation and Research (CDER).  The first award is a ... Warehouse, and the second award supports the expansion of ... Mortara has a long-standing relationship with ...
... Sept. 30 HHS, Agency for Healthcare Research and ... grants and contracts to support projects that will help ... evidence of effectiveness. The funding announced today covers all ... HHS Secretary by AHRQ.   The projects ...
Cached Medicine Technology:Mortara Instrument Announces ECG Warehouse Contract Awards With US FDA 2HHS Awards $473 Million in Patient-Centered Outcomes Research Funding 2
(Date:3/30/2015)... Daily sun exposure, stressors and environmental ... wrinkles, folds and other giveaways of age. However, advances ... women to hit the pause button, delaying the impact ... tuck or hack to rejuvenate any facial feature. , ... Surgery (AAFPRS) explores the intricacies of The Aging ...
(Date:3/30/2015)... Considered to be the best assessment tool for ... community, this next generation of the IT Audit ... data and frameworks with virtually endless possibilities. These new ... logic features are a technological force to be reckoned ... “The IT Audit Machine is just one of the ...
(Date:3/30/2015)... March 30, 2015 Cutting-edge doctors and ... 2015 Conference because of the opportunities to present and ... conference will highlight parents of recovered children, who will ... Romaniec, will debut her book Victory over Autism: Practical ... Free copies of Victory over Autism will be available ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Developing new ... to the use of cellular models that recapitulate only ... entirety of the disease. , A company that ... cells to precise specifications has created iPSC-derived cardiomyocytes ... environmentally and genetically driven in vitro models of Diabetes ...
(Date:3/29/2015)... At the 2015 International Health Racquet & ... the new Fonda wall mounted heater and a continuing ... and facilities managers with saunas smaller than 425 cubic ... the Fonda heater. With an attractive seamless red ... upgrade for a sauna, especially when mounted in front ...
Breaking Medicine News(10 mins):Health News:New AAFPRS Infographic Addresses Concerns and Provides Aging Face Solutions 2Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:Helo Commercial Introduces Fonda Sauna Heater and Sauna and Steam Continuing Education Program at IHRSA 2
... Sweden have successfully transferred a uterus into a sheep, and ... They explained that the operation proves that a womb can ... an animal. ,Tests that were conducted on the ... surgery and is continuing to function normally. It was explained ...
... been found to have a role in the treatment of ... // ,The results of the study have been ... Journal of Medicine, which has revealed that this immunosuppressive drug ... as well as the quality of life for people with ...
... forensic medicine lecturer faces disbarment from Medical Council of India (MCI) ... the same time, which is against the rules of the MCI. ... his employment with Sion Hospital. ,If he is debarred, ... has already been debarred till July 31, 2007 for an earlier ...
... to buy Swedish medical company Biacore to complement its ... announced. // ,The Fairfield, Connecticut-based GE will ... for 3.22 billion Swedish kroner ($438 million). ... percent stake in Uppsala, Sweden-based Biacore, supports the bid, ...
... to thee?' - sounds odd?,But it is a dyslexic's mode ... , The learning disability, dyslexia, has a genetic component, ... opens up ways for treatment. , Dyslexia ... Network report that they have located the dyslexia gene, denoted ...
... insisted that hospital consultants who are not referring patients to ... concerns that the NTPF has only seen a fraction of ... ,NTPF chairman Pat O'Byrne commented that there was no ... months for a surgical procedure. ,"There's no doubt ...
Cached Medicine News:Health News:Scientists Claim Human Womb Transplants Possible 2Health News:Cancer Drug to Treat Scleroderma Lung Disease 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: